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Arterial calcification, a risk factor of cardiovascular events, develops with differentiation of vascular
smooth muscle cells (VSMCs) into osteoblast-like cells. Cyclophilin A (CypA) is a peptidyl-prolyl isom-
erase involved in cardiovascular diseases such as atherosclerosis and aortic aneurysms, and rho-
associated protein kinase (ROCK) is involved in the pathogenesis of vascular calcification. CypA is
secreted in a ROCK activity-dependent manner and works as a mitogen via autocrine or paracrine
mechanisms in VSMCs. We examined the involvement of the ROCK-CypA axis in VSMC calcification
induced by inorganic phosphate (Pi), a potent cell mineralization initiator. We found that Pi stimulated
ROCK activity, CypA secretion, extracellular signal-regulated protein kinase (ERK) 1/2 phosphorylation,
and runt-related transcription factor 2 expression, resulting in calcium accumulation in rat aortic smooth
muscle cells (RASMCs). The ROCK inhibitor Y-27632 significantly suppressed Pi-induced CypA secretion,
ERK1/2 phosphorylation, and calcium accumulation. Recombinant CypA was found to be associated with
increased calcium accumulation in RASMCs. Based on these results, we suggest that autocrine CypA is
mediated by ROCK activity and is involved in Pi-induced ERK1/2 phosphorylation following calcification
signaling in RASMCs.
© 2019 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Arterial calcification associated with aging, atherosclerosis,
diabetes mellitus, and renal failure is a major risk factor for car-
diovascular events.1,2 Vascular calcification in the medial layer is
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d/4.0/).diabetes mellitus and past vascular disease history.1 Medial calci-
fication is thought develop as a result of vascular smooth muscle
cell (VSMC) differentiation into osteoblast-like cells, followed by
their apoptosis.3,4 Therefore, clarifying the mechanisms of VSMC
differentiation will help in understanding the pathophysiology of
vascular calcification.
Rho-associated protein kinase (ROCK) is involved in VSMC
contraction, migration, and proliferation, and plays important roles
in the pathogenesis of cardiovascular diseases (CVD). Recently,
several studies have indicated the involvement of the rho-ROCK
pathway in VSMC calcification, with ROCK inhibition suppressingnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
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VSMCs.3,5 Extracellular-signal regulated kinase (ERK) 1/2 is also
known to mediate Pi-induced osteogenic responses via the phos-
phorylation of runt-related transcription factor 2 (runx2) in
VSMCs.6 However, the involvement of the ROCK-ERK1/2 signaling
pathway in VSMC osteoblast-like differentiation and calcification
remains unclear.
Cyclophilin A (CypA) is a highly-conserved chaperone protein
which possesses peptidyl-prolyl isomerase activity, and contributes
to aortic aneurysms,7 atherosclerosis,8 and other forms of CVD. In
our previous study, we demonstrated that CypA expression is
upregulated at the aortic wall in an aneurysmmouse model.9 CypA
works via autocrine or paracrine mechanisms,10 which are medi-
ated by ROCK activity.11 Secreted CypA stimulates cell proliferation,
senescence, inflammatory responses, and apoptosis in several cell
types7,8,10 via binding to the CypA receptor CD147.12 Autocrine CypA
is involved in osteoblast differentiation13 and bone metabolism,14
further supporting its role in CVD.
Based on these findings, we hypothesized that CypA contributes
to VSMC osteoblast-like differentiation and vascular calcification.
To answer this question, we examined the pathological roles and
signaling pathways of ROCK, CypA, and ERK1/2 activities in VSMC
calcification induced by inorganic phosphate (Pi), a potent cell
mineralization initiator.
2. Materials and methods
2.1. Ethics statement
This study conformed to the Guide for the Care and Use of
Laboratory Animals.15 All animal procedures were performed in
accordance with the guidelines of the Animal Research Committee
of the University of Tokushima Graduate School. Protocols were
approved by the Tokushima University Institutional Review Board
for Animal Protection. Paraffin-embedded human samples were
obtained from stored autopsy specimens at the Department of
Pathology, Tokushima University, where each autopsy was con-
ducted at the Tokushima University Hospital with consent for
research use. The protocol was approved by the Ethics Committee
of Tokushima University Hospital in accordance with the Declara-
tion of Helsinki.
2.2. Cell culture and treatments
Rat aortic smooth muscle cells (RASMCs) were isolated from
male SpragueeDawley 200e250 g rats as previously reported.16
These cells were cultured in Dulbecco's Modified Eagle's Medium
(DMEM) (Sigma, MO, USA) with 10% FBS. For each experiment, we
used 70e90% confluent cultured cells at 37 C and 5% CO2. Cells
were treated with 0.3 or 3 mM dibasic sodium phosphate (Wako,
Osaka, Japan) as inorganic phosphate (Pi) stimulation for each
assay. Cells were treated with Rho-associated protein kinase
(ROCK) inhibitor Y-27632 (Wako) (0.1, 1, and 10 mM), ERK1/2 in-
hibitor PD98059 (Santa Cruz Biotechnology Inc., TX, USA) (10 mM),
and CypA inhibitor 239836 (Merck, Darmstadt, Germany) (1, 10,
30 nM) 30 minutes prior to Pi stimulation.
2.3. Measurement of calcium accumulation
RASMCs were stimulated with Pi or cyclophilin human re-
combinant A (1e165) (Atgen Co. Ltd., Gyeonggi-do, Korea),
which shows more than 96% homology with rattus CypA, for 2
or 8 days, after seeding to a 12-well plate. Calcium accumulated
on the dish was eluted during an overnight shake with 1 M HCl.
The calcium quantity in the eluted liquid was detected in anMXB (methylxylenol blue) assay using a Calcium-E (Ca-E) Test
(Wako), with absorbance measured at 610 nm using a micro-
plate reader.
2.4. Measurement of alkaline phosphatase (ALP) activation
RASMCs were stimulated with Pi for 2 or 8 days after seeding to
24-well plate. Cells were lysed using phosphate buffered saline
(PBS) including 1% Triton X, and absorbance at 410 nm was
measured using a Lab Assay ALP kit (Wako) after a p-nitro-
phenylphosphate substrate reaction. Protein content was quanti-
fied using the Bradford assay.
2.5. Von Kossa staining
RASMCs were stimulated with Pi for 8 days after sowing to a
35mm dish. After being fixedwith 4% formalin for 30minutes, cells
were stained for 60 minutes in aqueous silver nitrate under UV
lighting. Cells were deoxidized and fixed in 5% sodium thiosulfate
aqueous solution, washed with PBS, and filmed using EXILIM
(CASIO, Tokyo, Japan).
2.6. Animal experiments
BKS.Cg- þ Leprdb/þLeprdb/Jcl mice (db/db mice), as models for
type 2 diabetes were purchased from Nippon CLEA (Tokyo, Japan),
and maintained with free access to water and food. BKS.Cg-mþ/
mþ/Jcl background mice were used as controls. To allow the for-
mation of vascular lesions, mice were maintained until twelve
months of age with food and water containing normal quantities
of phosphate and glucose. Mice were then anesthetized with
pentobarbital (150 mg/kg i.p.) and aortic sections were removed.
After fixing in 4% paraformaldehyde, samples were embedded
with paraffin and 5 mm slices were prepared as previously
reported.17
2.7. Western blotting
Proteins from mouse aortas and cultured RASMCs were
analyzed via western blotting,17 using antibodies detecting CypA,
runx2 (Abcam, MA, USA), phospho-ERK1/2, total-ERK1/2 (Cell
Signaling Technology, MA, USA), phospho-myosin phosphatase
targeting subunit (MYPT) 1, total-MYPT1, and b-actin (Santa Cruz
Biotechnology, Inc., Dallas, Texas, USA) at 1:1000 dilution. Activa-
tion of ROCK was evaluated by detecting the percentage of phos-
phorylated MYPT1, an intrinsic substrate of ROCK, and normalizing
to total-MYPT1.
2.8. Histological analysis
Prepared mouse aortas were stained with hematoxylin and
eosin (H&E) or immunostained using runx2 antibody and CypA
antibody.18 Human samples including normal heart, normal
aorta, aorta with plaque, and basilar artery with plaque were
treated in a similar fashion. A Dako ChemMate Envision kit/HRP
(DAB) Universal (Dako, Glostrup, Denmark) was used for DAB
staining.
2.9. Enzyme-linked immunosorbent assay (ELISA) for CypA
Conditioned media (CM) were collected and concentrated using
the ND Protein Precipitation Kit (National Diagnostics Inc., NC, USA)
to measure CypA secretion into CM. Concentrated CM were sub-
jected to ELISA,19 wherein samples were applied to 96-well plates
and solid-phased by overnight incubation at 4 C. After blocking
T. Tsuda et al. / Journal of Pharmacological Sciences 142 (2020) 109e115 111with 3% BSA, 0.05% Tween 20, and PBS-T, CypA antibody was added
and incubated overnight at 4 C. ECL Rabbit IgG and HRP-linked
whole Ab (GE Healthcare, Bucks, UK) were used as secondary an-
tibodies. TMB (3,30,5,50- tetramethylbenzidine) substrate solution
as reaction buffer and 1 M sulfuric acid (Wako) as stopping buffer
were added, and absorption at 450 nm was measured.2.10. Statistical analysis
All experiments were performed with 3e6 replicates. Results
are expressed as mean ± standard deviation. Differences were
assessed using Student's t test for two comparisons, or a two-way
analysis of variance (ANOVA) for multiple comparisons, where
p < 0.05 was considered to indicate statistical significance.Fig. 1. Pi stimulation increases ALP activity and calcium accumulation in RASMCs. (A) AL
Concentration response of Pi-stimulated ALP activity after 8 days' stimulation. Pi-induced c
Calcium E-test Wako (D) after 8 days' stimulation. (E) RASMCs were stimulated with 3 m
evaluated using western blotting. Upper panels show representative blots and the lower grap
2 inhibitor PD98059. Values were analyzed using two-way ANOVA for repeated measures.3. Results
3.1. Pi stimulation increases ALP activity and calcium accumulation
in RASMCs
ALP activity increased after 8 day treatment with 3 mM Pi
(Fig. 1A, B), and Von Kossa staining showed brown deposits indi-
cating calcium accumulation (Fig. 1C). Results from the MXB assay
also showed a significant increase in calcium accumulation
(Fig. 1D). Pi stimulation caused an immediate increase in ERK1/2
phosphorylation, with a peak occurring 10 minutes after stimula-
tion (Fig. 1E). Pretreatment with the ERK1/2 inhibitor PD98059
suppressed Pi-induced ALP activity (Fig. 1F). These findings indicate
that Pi-induced RASMC calcification was mediated by ERK1/2
activity.P activity in RASMCs after stimulation with vehicle or 3 mM Pi for 2 or 8 days. (B)
alcium accumulation was visualized by Von Kossa staining (C) and quantified using a
M Pi for the indicated time and phosphorylated- and total ERK1/2 expressions were
h shows intensity. (F) Pi-induced ALP activity was measured with or without the ERK1/
*P < 0.05 vs. control, yP < 0.05 vs. Pi alone.
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To examine the involvement of ROCK in Pi-induced calcification
signaling, we evaluated phosphorylation of the ROCK substrate,
MYPT. MYPT phosphorylation increased immediately and peaked
at 10 minutes after Pi stimulation in RASMCs (Fig. 2A), and phos-
phorylationwas inhibited by pretreatment with the ROCK inhibitor
Y-27632 in a concentration-dependent manner (Fig. 2B). ERK1/2
phosphorylation was also suppressed by pretreatment with Y-
27632 (Fig. 2C), and ROCK inhibition by Y-27632 also significantly
suppressed Pi-induced ALP activity and calcium accumulationFig. 2. Effect of Pi-induced ROCK activity on calcification signaling. (A) Time-course of Pi-ind
Y-27632 for 30 min, then stimulated with Pi. MYPT phosphorylation (B) and ERK1/2 phos
accumulation (E) were measured after 8 days' Pi stimulation with or without Y-27632. Valu
yP < 0.05 vs. Pi alone.(Fig. 2D, E). These results indicate that ROCK activity is involved in
the Pi-induced calcification pathway by mediating ERK1/2 phos-
phorylation in RASMCs.
3.3. Expressions of runx2 and CypA in aortas from diabetic mice
and clinical atherosclerotic plaque samples
Vascular lesions such as atheroma formation could not be
observed by H&E staining (Fig. 3B). Immunostaining and Western
blot analyses indicated greater expression of runx2 and CypA in
aortas from db/db mice compared with control mice (Fig. 3AeC),uced MYPT phosphorylation in RASMCs. Cells were pretreated with the ROCK inhibitor
phorylation (C) were measured using western blotting. ALP activity (D) and calcium
es were analyzed using two-way ANOVA for repeated measures. *P < 0.05 vs. control,
Fig. 3. Expressions of runx2 and CypA in aortas from diabetic mice or patients with
atherosclerotic plaques. Runx2 expression in aortas from control or db/db mice was
detected using western blotting (A) and immunohistochemistry (B). (C) CypA
expression was analyzed in aortas from control or db/db mice. Right-hand panels show
magnifications of left-hand panels. (D) CypA expressions in (i) myocardium, (ii) normal
aorta, (iii) basilar artery with plaque, and (iv) aorta with plaque were detected using
immunohistochemistry. Normal aorta and myocardium were sampled from healthy
subjects. Atherosclerotic basilar artery and aorta with plaques were obtained from a
diabetic patient. Each panel shows a representative picture. Scale bar: 0.1 mm.
T. Tsuda et al. / Journal of Pharmacological Sciences 142 (2020) 109e115 113and human arteries from autopsy samples similarly showed greater
CypA expression in patients with diabetes mellitus (Fig. 3D). CypA
was more abundant in myocardium and leukocytes compared to
vascular wall cells in healthy subjects (Fig. 3Di, ii). However,
increased CypA expression was observed in the basilar artery(Fig. 3Diii) and aorta with plaque (Fig. 3Div), but not in the normal
coronary artery (Fig. 3Di) or aorta (Fig. 3Dii).3.4. CypA is involved in Pi-induced calcification signaling in
RASMCs
CypA secretion increased under 3 mM Pi stimulation with a
peak 10 minutes after stimulation (Fig. 4A) but was inhibited by
pretreatment with Y-27632 (Fig. 4B). The CypA inhibitor sup-
pressed expression of Pi-induced ERK1/2 activation, runx2
expression, and calcium accumulation (Fig. 4CeE). Moreover,
treatment with recombinant CypA increased calcium accumulation
in RASMCs (Fig. 4F). These results suggest that autocrine CypA is
mediated by ROCK activity and is involved in Pi-induced ERK1/2
phosphorylation and subsequent calcification in RASMCs.4. Discussion
Consistent with previous reports,3,5 our results indicate that the
ROCK inhibitor Y-27632 inhibited the Pi-induced calcification
signaling pathway, including CypA secretion (Fig. 4B), ERK1/2
phosphorylation (Fig. 2C), runx2 expression (Fig. 4D), ALP activity,
and ultimately calcium accumulation (Fig. 2D, E) in RASMCs. This
suggests that ROCK activity might trigger high phosphate-induced
VSMC calcification. Therefore, ROCK inhibition may be an effective
strategy for protecting against vascular calcification.
This study is the first to demonstrate the involvement of CypA in
vascular calcification. CypA inhibition suppressed Pi-induced ERK1/
2 phosphorylation and subsequent runx2 expression (Fig. 4C, D) in
a manner similar to that of ROCK inhibition (Figs. 2C and 4D). Since
the ROCK inhibitor Y-27632 suppressed CypA secretion in culture
media under Pi stimulation (Fig. 4B), ROCK may be active upstream
of autocrine CypA, after ERK1/2 phosphorylation. This is further
supported by previous findings that CypA secretion requires ROCK
activity-dependent vesicle formation in VSMCs.20 Treatment of
RASMCswith recombinant CypA peptide instead of Pi indicates that
CypA alone can induce a comparable level of calcium accumulation
(Fig. 4F). These in vitro findings strongly support the hypothesis that
extracellular CypA may work as a mitogen to induce the calcifica-
tion pathway in VSMCs.
Several clinical studies have previously demonstrated increased
plasma levels of CypA in patients with type 2 diabetes mellitus,
diabetic nephropathy, and carotid stenosis,21e23 implying the pos-
sibility of CypA as a risk marker for cardiovascular events. Our
findings demonstrate that CypA expression is upregulated in
atherosclerotic or diabetic vasculature in both human patients and
mice (Fig. 3). This is especially evident in the medial area of the
aorta in diabetic db/db mice (Fig. 3C). A similar localization of
runx2, a marker of osteoblast-like cell differentiation, could also be
observed (Fig. 3A, B). These observations imply that increased CypA
has a role in vascular calcification.
The role of the ROCK-CypA axis in Pi-induced VSMC calcification
suggests that inhibitors of ROCK or CypA may be effective against
VSMC calcification. However, some reports indicate an opposite
relationship, wherein the rhoA-ROCK pathway negatively regulates
cell calcification and osteoblast-like cell differentiation.24,25 Chen
et al. reported that the ROCK pathway increased the uptake of
fetuin-A, an inhibitory factor of vascular calcification, working as a
negative regulator.24 Their observations showed opposite results to
our present study. ROCK seems to have multifaceted roles in
calcification signaling dependent of the calcification inducer, cell
types, and so on. Interestingly, Gu et al. reported that ROCK activity
is associated with increased nodule formation of valvular intersti-
tial cells, but ROCK inhibition also increased ALP activity.25 These
Fig. 4. Autocrine CypA mediates Pi-induced calcification signaling in RASMCs. Conditioned media (CM) after Pi stimulation were collected and condensed to measure CypA secreted
from RASMCs. Panel (A) shows the time course and panel (B) shows the effect of the ROCK inhibitor Y-27632. The effects of 30 min' pretreatment by CypA inhibitor (CypAi) on ERK1/
2 phosphorylation (C), runx2 expression (D), and calcium accumulation (E) were examined using western blotting and Calcium-E test Wako. Upper panels show representative blots
and lower panels show the quantified intensity. (F) Human recombinant CypA (10 ng/mL) was added into culture media for 8 days, after which RASMCs were harvested and calcium
accumulation was measured. Two-way ANOVA for (A) to (E) and Student's t-test for (F) were performed. *P < 0.05 vs control, yP < 0.05 vs. Pi alone.
T. Tsuda et al. / Journal of Pharmacological Sciences 142 (2020) 109e115114opposing roles of ROCK activity in vascular calcification and cell
mineralization remain controversial.
One study suggests CypA may positively regulate cell mineral-
ization, with CypA knockout (Ppia/) mice showing less skeletal
volume compared to wildtype mice, and CypA overexpression
leading to an increase in osteogenic markers such as ALP activity
and runx2 expression.14 However, cyclosporine A, a major inhibitor
of CypA peptidyl-prolyl isomerase activity, aggravates VSMC calci-
fication.26 These findings contradict our observation that CypA in-
hibition suppressed Pi-induced ERK1/2 phosphorylation and runx2expression (Fig. 4C, D). The CypA inhibitor 239836 which was used
in this study shows 27 timesmore potent peptidyl-prolyl isomerase
inhibitory activity than cyclosporine A, according to the commer-
cial instruction of the reagent. The comparison of cyclosporine A
and the CypA inhibitor 239836 will be needed to confirm the effi-
cacy of CypA inhibition on cell calcification.
As demonstrated in the present study, vascular calcification is
dependent on the same molecular pathways that are associated
with intracellular signaling during bone mineralization in vitro,
including ROCK, ERK1/2, and runx2 pathways. However, vascular
T. Tsuda et al. / Journal of Pharmacological Sciences 142 (2020) 109e115 115and other ectopic calcification occurs during bone loss or osteo-
porosis in vivo.27 Therefore, further experiments should be carried
out to clarify the pathophysiological roles of the ROCK-CypA axis in
vascular calcification and the clinical effectiveness of ROCK or CypA
inhibition on vascular calcification in a comprehensive manner.
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